GLOBUS MEDICAL financials
$75.69+1.22%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $789.6M | $759.9M | $826.4M | $769.0M | $745.3M | $598.1M | $657.3M | $625.7M | $629.7M | $606.7M | $616.5M | $383.6M |
| Gross profit | $548.2M | $525.8M | $565.3M | $516.5M | $496.6M | $402.7M | $393.9M | $355.2M | $369.7M | $365.2M | $351.0M | $248.2M |
| Gross margin | 69.4% | 69.2% | 68.4% | 67.2% | 66.6% | 67.3% | 59.9% | 56.8% | 58.7% | 60.2% | 56.9% | 64.7% |
| Operating income | $182.4M | $150.4M | $169.3M | $137.4M | $76.1M | $97.0M | $60.3M | $48.1M | $49.6M | $10.4M | $25.7M | $46.0M |
| Net income | $151.6M | $124.3M | $140.6M | $119.0M | $202.8M | $75.5M | $26.5M | $51.8M | $31.8M | -$7.1M | $15.0M | $998.0K |
| Net margin | 19.2% | 16.4% | 17.0% | 15.5% | 27.2% | 12.6% | 4.0% | 8.3% | 5.0% | −1.2% | 2.4% | 0.3% |
| Diluted EPS | $1.10 | $0.90 | $1.03 | $0.88 | $1.49 | $0.54 | $0.19 | $0.38 | $0.23 | $-0.05 | $0.11 | $0.01 |
| EBITDA | $265.0M | $231.8M | $250.3M | $206.1M | $193.4M | $163.7M | $145.0M | $116.6M | $119.7M | $91.5M | $26.0M | $86.3M |
| Operating cash flow | $209.7M | $202.4M | $248.6M | $249.7M | $77.9M | $177.3M | $210.3M | $203.7M | $54.1M | $52.6M | $91.7M | $46.1M |
| Free cash flow | $176.6M | $162.7M | $202.4M | $213.9M | $31.3M | $141.2M | $193.2M | $161.7M | $26.3M | $24.0M | $68.8M | $24.5M |
| Diluted shares | 137.4M | 138.2M | 136.6M | 135.4M | 136.5M | 139.8M | 141.1M | 138.1M | 137.0M | 135.4M | 139.3M | 115.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $507.7M | $561.0M | $526.2M | $371.8M | $229.4M | $461.3M |
| Short-term investments | $87.4M | $68.9M | $31.1M | $18.8M | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $5.49B | $5.44B | $5.30B | $5.10B | $4.96B | $4.71B |
| Total liabilities | $719.7M | $707.2M | $729.5M | $696.8M | $665.4M | $623.1M |
| Shareholders' equity | $4.77B | $4.73B | $4.57B | $4.40B | $4.30B | $4.09B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology